I think clearly those that stayed in Bullzeye concluded that the company is worth a LOT more once it is full fleshed out, even allowing for funding rounds. Sprott recently said Bullzeye could eventually double EMR valuation. If that's the case, then the 40% of Bullzeye not in EMR hands will be very valuable. Those that sold to EMR perhaps were happy to have a way to cash-out, and may have been holders for many years and acquired the shares early on and hence cheaply.
There is no doubt a well executed Bullzeye works for EMR shareholders.
Regarding the court case, it's in the prospectus in the broad sense who is taking who to court. Bit too complicated for me to work it all out
EMR Price at posting:
$1.14 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)